New Two-Drug combo tested in fight against lymphoma
NCT ID NCT06029309
Summary
This study is testing a combination of two drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma, a type of blood cancer. The first part aims to find the safest and most effective dose. The second part will see how well this dose combination works to put the cancer into remission. It is for adults whose cancer has come back after prior treatment or who are newly diagnosed but not eligible for intensive chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.